Background: Chordomas are rare neuraxial tumors arising from remnants of primitive notochord. They are generally slow-growing malignant neoplasms. Only four adult cases of multicentric chordomas have been reported, all with aggressive and rapid growth. Here, we present an unusual case of indolent multicentric chordomas involving cervical and thoracic spine, sacrum, and calvarium.
Case Description: A 60-year-old male was found to have multiple lesions throughout his neuroaxis incidentally on workup for colitis. A needle biopsy documented the diagnosis of chordoma. This has been followed for more than 4 years with no progression.
Conclusion: We present the first reported case of indolent multicentric chordomas. Due to the extreme rarity of indolent multicentric chordomas, close follow-up is needed and recommended.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479634 | PMC |
| http://dx.doi.org/10.25259/SNI_507_2022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutibacterium acnes infective endocarditis-an emerging pathogen.
Eur J Cardiothorac Surg
November 2024
Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.
Article Synopsis
- * It found that 269 patients (3.1%) had C. acnes endocarditis, primarily affecting younger individuals with native valves, while prosthetic valve cases were more frequent in older age groups.
- * Although survival rates were better for native valve cases, the incidence of C. acnes endocarditis is concerning and requires specialized diagnostic methods, but surgical outcomes were generally acceptable.
Diabetic foot complications that lead to lower extremity amputations pose a significant challenge to the entire global health system. In this multicentre clinical trial, 26 patients with chronic Wagner one diabetic foot ulcers (DFUs) were treated with a unique human keratin matrix graft applied either weekly or bi-weekly, in addition to standard of care. The hypothesis was that bi-weekly application would be similar to weekly application.
View Article and Find Full Text PDFPustular mycosis fungoides has a poor outcome: a multicentric clinicopathological and molecular case series.
Br J Dermatol
December 2024
Department of Pathology, Henri Mondor University Hospital, Assistance Publique - Hôpitaux de Paris, Créteil, France.
Background: Mycosis fungoides (MF) usually has an indolent course. However, some patients develop more aggressive disease and few prognostic parameters have been identified. Isolated cases of pustular MF (pMF) suggest an unfavourable prognosis.
View Article and Find Full Text PDFRedefining prostate cancer risk stratification: a pioneering strategy to estimate outcome based on Ki67 immunoscoring.
Biomark Res
August 2024
Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/ CI-IPOP@ RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
Article Synopsis
- Accurate diagnosis and risk assessment for prostate cancer (PCa) patients is crucial for ensuring the best treatment outcomes, especially for those with low- and intermediate-risk disease who may opt for active surveillance (AS).
- A study developed risk calculators based on cancer biomarkers, such as Ki67 and KLF8 levels, to better distinguish which patients might benefit from more proactive interventions.
- The resulting prognostic model, known as ProstARK, showed promising accuracy in predicting biochemical recurrence-free survival, but further validation in larger studies is needed to confirm its effectiveness for patient selection in AS protocols.
Nordic inflammatory bowel disease treatment strategy trial: protocol for the NORDTREAT randomised controlled biomarker-strategy trial.
BMJ Open
July 2024
Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
Introduction: The absence of reliable prognostic markers poses a challenge to the management of inflammatory bowel disease (IBD). Patients with aggressive disease may not receive sufficient treatment with conventional 'step-up' therapy, whereas a top-down approach may expose patients with indolent disease to unnecessary treatment-related toxicity. The objective of the Nordic IBD treatment strategy trial (NORDTREAT) is to assess the feasibility of personalised therapy by stratifying patients according to a prognostic serum protein signature at diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!